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(57) ABSTRACT 
Acoustic wave devices coated with a biolayer are described 
for the detection target bio-molecules. The acoustic wave 
device is connected in an oscillator circuit, and the frequency 
shift li.f resulting from a biomolecular event is recorded. 
Further described are the use of Rayleigh wave surface acous-
tic wave devices for vapor phase detection as well as quartz 
crystal micro balance devices for liquid phase measurements. 
A biofilm on the surface of the acoustic wave device com-
prises of a layer of antibodies raised against a specific target 
molecule or antigen. Signatures for detection events are pre-
sented in the form of frequency shifts li.f(t). 
9 Claims, 6 Drawing Sheets 
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SYSTEMS AND METHODS FOR 
MOLECULAR RECOGNITION 
CROSS-REFERENCE TO RELATED 
APPLICATION(S) 
This application claims priority to U.S. Provisional Patent 
Application No. 60/476,103 filed Jun. 5, 2003, which is 
hereby incorporated by reference in its entirety. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH 
TECHNICAL FIELD 
The invention concerns acoustic wave sensors. More spe-
cifically, the invention relates to the detection of biochemical 
materials by use of acoustic wave detection. 
BACKGROUND 
2 
distinguishing characteristics of detection events. One such 
static model is the Sauerbrey equation, i.e.,: 
2 ,i 
llDf = _--1..'!..!2 
Va Pr 
10 
where li.f is the resonator frequency shift; f0 is the resonator 
center frequency; Ps is the mass density per m2 of analyte 
attached to the surface; Va is the acoustic wave velocity in the 
resonator, and p" is the volume mass density of resonator 
material. (further described in "Use of quartz vibrator for 
15 
weighing thin films on a micro balance," Z Phys., vol. 155, pp. 
206-210, 1959.). By failing to account for changes in 
response over time, such models are often inadequate to dis-
tinguish molecular recognition events from noise. 
Acoustic wave "biosensors" are distinguished from chemi-
20 cal sensors in that they use a molecule of biological origin 
(e.g., antibody, cell, enzyme, protein) immobilized onto a 
surface as the chemically sensitive film on a device. In the 
prior art, the detection of the presence of entities of biological 
origin, such as proteins or cells, has taken place in liquids as The highly specific and complex nature of olfactory sens-
ing systems has inspired researchers to develop vapor phase 
chemical detection systems, commonly referred to as "elec-
tronic noses." These devices and systems are currently being 
used in biotechnology, as well as applications in medicine, the 
environment, the food industry, and most recently law 
enforcement applications. Interdiction efforts continue in the 
search for technologies which can provide an inexpensive 
alternative to dogs as detectors of narcotics and explosives. 
One of the principal motivations for the development of elec-
tronic noses for such applications is the expense associated 
with the handling, training, and care of such dogs, Further- 35 
more, it is often unclear what chemicals the dogs are actually 
detecting, and response vary considerably amongst dogs. As 
25 a requirement. Accordingly, there is a need for an acoustic 
sensor and models for signature recognition which have one 
or more of the following features: (1) allow for the detection 
of targets other than biomolecules, (2) do not limit the detec-
tion environment to the liquid phase; (3) allow detection of 
30 bio-molecules in the vapor phase; ( 4) allow for the detection 
of molecular recognition events through time-dependent sig-
natures, to improve accuracy and speed of detection. 
SUMMARY 
The invention includes acoustic wave biosensors that uti-
lize bio-molecules to achieve molecular recognition in the 
vapor phase and liquid phase as well. The techniques 
described herein for detection of analytes in the vapor phase 
may be used to recognize the presence of various airborne 
analytes that may be of interest, including small molecules 
an example, not all dogs do respond to the same cocaine 
sample. Although the dogs have proved to be a highly useful 
40 
tool in detecting illicit materials, they have inherent limita-
tions in reliability, as one would never accept data from an 
instrument without having a solid idea of the physical mecha-
nism behind a detection event. 
such as cocaine; many examples of such airborne analytes 
shall be readily apparent to those skilled in the art. In non-
limiting embodiments of the invention, monoclonal antibod-
Acoustic sensors represent a long-standing an approach for 
high-precision sensing. Quartz crystal microbalances 
(QCMs) have been utilized since the 1950s to monitor the 
thickness of metals being deposited on wafers in evaporation 
systems. Such sensors have leveraged investments in other 
technologies, namely, oscillator designs and electronic fre-
quency counters. In addition, the investments in frequency 
control and radar during World War II and for the quarter 
century that followed led to a detailed understanding of the 
temperature characteristics of quartz, largely at the Ft. Mon-
mouth, N.J., Army Research Lab in the United States. In cuts 
of quartz such as the AT-cut used for QCM, the linear expan-
sion of the material with increasing temperature is compen-
sated by an increase in the acoustic velocity such that the 
round trip delay for an acoustic wave in a resonator does not 
vary with temperature. However, current implementations of 
QCMs, as used to detect chemicals in the liquid phase, suffer 
from the inability to distinguish molecular detection events 
from noise, such as the binding of extraneous substances to 
the detection device. Furthermore, existing models of recog-
nition events are static, and do not account for time variations 
in the state of detection devices, and thereby ignore important 
45 ies are used for the molecular recognition; non-limiting 
examples of such monoclonal antibodies include IgG mono-
clonal antibodies. In embodiments of the invention, antibod-
ies specific for a target antigen are utilized as a chemically 
specific receptor molecule. Embodiments of the invention 
50 include a database of signatures of responses that are related 
to a molecular recognition event between antibody and anti-
gen. These signatures may include frequency shifts, recorded 
before, during, and after binding events (i.e., a binding of an 
antigen to the antibody), which are used to identify the occur-
55 rence of a binding event. Further embodiments include meth-
ods for evaluation of such signatures, through models based 
on time-dependent perturbation theory. Embodiments of the 
invention also enable the recognition of target molecules in 
liquid samples by exposing samples which may have the 
60 target molecule to an active sensor, while exposing reference 
samples of the liquid known not to contain the target to a 
reference sensor. In some embodiments, the active sensor and 
reference sensor may be physically proximate, and otherwise 
identically disposed. In some such embodiments, a frequency 
65 plot may be monitored, which subtracts a resonance fre-
quency of the reference sensor from that of the active sensor, 
in order to detect signature changes in frequency character-
US 7,413,892 B2 
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istic of the presence of the target molecule at the active sensor. 
These and other embodiments are described more particu-
larly herein. 
FIGURES 
FIG. 1 illustrates structural formulas of examples of sub-
stances detectable by embodiments of the invention. 
FIG. 2 illustrates a delay-line form of a Surface Acoustic 
Wave detector, configured in accordance with embodiments 
of the invention. 
FIG. 3 illustrates a response of the Surface Acoustic Wave 
detector to target molecules, in accordance with embodi-
ments of the invention. 
FIG. 4 illustrates a response of a device configured to 
identify substances in vapor form, in accordance with 
embodiments of the invention. 
4 
C. Detection of Small Molecules 
1. Example ofVapor Phase Detection-Uranine 
As a non-limiting, illustrative example of vapor phase 
detection of small molecules, described herein is a method for 
detection ofuranine (fluorescein sodium salt); the chemical 
structure 100 of which is depicted in FIG. 1. The fluorescence 
ofuranine may be used to provide independent confirmation 
of the occurrence ofbinding events with the antibody film 202 
coated on the device, which are otherwise detected by the 
10 signature recognition techniques of the invention. Embodi-
ments of the invention utilize a vapor phase biosensor by 
immobilizing a mono layer of antibodies 202 onto the surface 
of a 250-MHz SAW device fabricated on ST-Quartz. In some 
such embodiments, the monolayer of antibodies may include 
15 anti-FITC antibodies. For the particular cut and propagation 
direction, the interdigitated transducer on the device gener-
ates a Rayleigh which has particle polarization in the saggital 
plane that is retrograde and decays within roughly one acous-
FIG. 5 illustrates a response of a sensor to a substance 20 
identified in a liquid phase, in accordance with embodiments 
tic wavelength from the surface. Such Surface Acoustic Wave 
(SAW) devices may obtain sensitivities of approximately 20 
Hz/pg with a detection limit on the order of a few picograms. 
of the invention. 
FIG. 6 illustrates a response of a sensor device to an 
example protein, in accordance with embodiments of the 
invention. 
DETAILED DESCRIPTION 
A. Introduction 
The following description presents many examples of 
vapor and liquid phase acoustic wave biosensors, as well as 
the signatures of responses that are related to molecular rec-
ognition that are related to molecular recognition events 
between antibodies and antigens. Methods are also described 
for evaluation of such signatures. The embodiments and 
examples described herein are for illustrative purposes only; 
many modifications, variations, and equivalents shall be 
readily apparent to those skilled in the art. In particular, sig-
natures are described herein for the vapor phase detection of 
small molecules, examples of which are uranine and cocaine. 
Other examples are presented for the detection of small and 
large molecules in the liquid phase. These examples are pre-
sented for illustrative purposes only, and many examples of 
molecules detectable by the invention shall be apparent to 
those skilled in the art. 
B. Detection Method and Apparatus 
Embodiments of the invention include an apparatus for the 
detection of biomolecules, as schematically depicted in FIG. 
2 200, which includes an acoustic wave device 200 coated 
with a layer of biological material, or bio-layer 202. In 
embodiments of the invention, the acoustic wave device 200 
is connected to an oscillator circuit, such that a frequency shift 
resulting from a bio-molecular event may be recorded; this 
frequency shift may be compared to a signature for a known 
bio-molecular event in order to detect/distinguish the bio-
molecular event. The bio-layer 202, which is disposed on a 
surface of the acoustic wave detector 200 may include a layer 
of anti-bodies responsive to a specific target molecule, or 
antigen. 
Embodiments of the invention allow for detection of bio-
molecules in vapor phase or liquid phase. In some embodi-
ments, a Rayleigh wave surface acoustic wave device may be 
used for vapor phase detection. In embodiments, quartz crys-
tal micro balance (QCM) devices may be used ofliquid phase 
measurements. 
To illustrate the sensing mechanism, as a non-limiting 
example a simple version of this device structure, a SAW 
delay line, is schematically illustrated in FIG. 2. This device 
25 may be connected into an oscillator circuit, allowing the 
frequency of oscillation can be measured with great preci-
sion. In embodiments of the invention, the SAW device and 
the oscillator circuit may share a physical housing. Other 
alternative form factors shall be readily apparent to those 
30 skilled in the art. 
In the example of a SAW delay line, when the antigen binds 
to the antibody, the acoustic velocity is decreased, and the 
oscillator frequency shifts to a lower value. In alternative 
embodiments, a SAW resonator may be used. In such 
35 embodiments, because a binding event might take place in 
either the reflector gratings or the transducer sections of the 
device, the frequency can increase or decrease in the presence 
of a binding event. Furthermore, while stiffness changes in 
the biofilm would increase the resonant frequency of a delay 
40 line SAW sensor, they may increase or decrease the frequency 
of a SAW resonator. 
FIG. 3 illustrates SAW resonator responses 300 to the 
introduction of uranine vapor past the SAW resonator device. 
In the depicted response 300, the response of a reference 
45 device and oscillator circuit taken simultaneously with the 
response from the coated SAW resonators has already been 
subtracted from the recorded responses presented. These ref-
erence device has been subjected to the same temperature 
environment as the sensor under test, but is not exposed to the 
50 analyte stream. The sensor data shown in FIG. 3 have already 
had the reference variation subtracted out; this resultant fre-
quency shift was measured and recorded. Antigen-antibody 
binding for the uranine vapor and the anti-FITC antibody film 
is shown to have occurred quickly through frequency shifts 
55 3 02. In FIG. 3, we present the response ofan anti-FITC coated 
device and an uncoated device to uranine vapor. The anti-
FITC coated device shows a radical frequency response 302 
and a fairly substantial shift in the baseline frequency 304. 
This permanent shift in the baseline frequency represents 
60 direct evidence of molecular recognition in the vapor phase. 
2. Example ofVapor Phase Detection-Cocaine 
In non-limiting embodiments of the invention, immobi-
lized antibodies for benzoylecgonine (BZE) 202 are used as 
the antibody film for positive detection of cocaine. FIG. 4 
65 presents 700 the response ofanti-FITC, anti-BZE, and hydro-
gel-only sensors to a 1-ng pulse of cocaine over 5-s intervals. 
The pulse was injected into a constant flow of 180 cubic 
US 7,413,892 B2 
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poses only; many alternative implementations shall be readily 
apparent to those skilled in the art. 
a. Detection of Proteins 
Embodiments of the invention enable the detection of tar-
get proteins. As an illustrative, non-limiting example, 
described herein is an application of the invention to detect 
the calmodulin, a plant protein significant for its role as a 
biomarker in embryonic development of seedlings; as will be 
apparent to those skilled in the art, the invention may be 
centimeters per minute ( ccm) to minimize the impact associ-
ated with a sudden pressure differential. The anti-BZE device 
702 has a far more dramatic instantaneous response than the 
anti-FITC device 704. Note also that there is little or no 
difference between the gel-only 706 and anti-FITC 704 
device responses. This characteristic response is independent 
of the SAW resonator device location within the sensor head 
which holds and facilitates the simultaneous sampling of four 
sensors. During the pulse cycles, a consistent relationship 
obtains between the sequence and the amount of frequency 
shift (li.f) on the presentation of cocaine vapor. In short, the 
magnitude of the frequency shifts can be depicted as follows: 
1\.f (during pulse cycle): Uncoated<Gel only<Anti-
FITC/gel «Anti-BZE/gel 
10 applied to a variety of target proteins In this example, the 
active sensor has an anti-calmodulin antibody immobilized 
on the surface, with 100 µl of 5 µg/ml calmodulin added to the 
TAE buffered solution. This represents the introduction of 
500 ng of calmodulin into the reservoir. The resulting tran-
These differences in the magnitude of the frequency shift 
between anti-BZE and other sensors are utilized, according to 
embodiments of the invention, for the establishment of a 
decision criterion for the real time cocaine detection. 
15 sient QCM response 1200 is shown in FIG. 6, by a downward 
shift in frequency. Other distinguishing features in the signa-
ture 1206 include overshoot and ringing followed by an 
asymptotic approach to a baseline shifted by a factor li.f1204. 
3. Liquid Phase Detection of Small Molecules 
Embodiments of the invention enable the detection of 20 
D. Models of Signatures for Binding Events 
Embodiments of the invention include models for binding 
events in the acoustic wave sensor devices 200, which are 
time-dependent, and accordingly constitute alternatives to the 
standard Sauerbrey equation. In some such models, the 
change in the resonant frequency li.w(t) is related to a change 
small molecules in the liquid phase. As an illustrative 
example, a QCM device, such as a 10-MHz commercially 
available QCM, may be used as the SAW device. Other suit-
able SAW devices shall be apparent to those skilled in the art. 
25 in the stiffness of the immobilized antibody film li.µ(t). One 
such example is presented by the following equation: In embodiments of the invention, detection of the target molecule is performed by use of a active sensor and a refer-
ence sensor; in some such embodiments, the active and ref-
erence sensors are physically proximate, such that that the 
only significant difference between the active sensor and 
passive sensor is that the molecular recognition event, i.e., the 30 
binding of the target molecule to the immobilized antibodies, 
occurs on the active sensor and does not occur on the refer-
ence sensor. Accordingly, a difference in resonant frequen-
cies between the two sensors is indicative of the molecular 
recognition event. In embodiments of the invention, resonant 
frequency changes may be monitored in real-time, and in 
particular, before, during, and after the molecular recognition 
event. This upward shift may be used as a signature to detect 
the occurrence of the molecular recognition event, and dis-
tinguish it from any noise, including noise caused by the 
adhesion of non-targeted biological materials to the reference 40 
and sensor. 
l(J Wuhf { [ /lµ(r)l} [ /lµ(t)l J llw=t n~pqµq -wllp(r)---y;- dlr+i llp(t)----y; +C 
where C is a constant to be utilized in satisfying the initial 
35 condition of a problem. 
As an illustrative, non-limiting example, the use of the a 
dual sensor detection device is described herein as used to 
detect a biological molecule in a liquid phase; in this example, 
the dual sensor detection device is used to detect increasing 45 
concentrations of uranine in blood sera. The resonant fre-
quency response 1100 of the detection event is presented in 
FIG. 6, in which the x-axis 1102 plots the elapsed time, and 
the y-axis 1104 shows the resonant frequency of the reference 
is subtracted from the reference frequency of the sensor. As 50 
illustrated in FIG. 5, the molecular recognition event 110 
corresponds to an upward shift in the frequency of the of the 
active sensor 1104. 
The response in FIG. 5 was obtained from the CM as 100 µl 
of a nanomolar solution of uranine was added to a 4:3(v/v) 55 
mixture of serum to Tris-acetate/EDTA (TAE) buffer. The 
reference crystal was prepared in the same fashion as the 
anti-uranine coated sensor, which used analkane-thiol attach-
ment protocol. Both sensors were fitted to a flow cell that 
allowed only one side of each crystal to be exposed to the 
liquid. Careful addition of 100 µl of 1-nM concentration of 60 
uranine followed by monitoring of the initial transient and 
subsequent frequency change was recorded and a sample 
transient curve is presented in FIG. 5. This concentration, 
diluted from the nanomolar uranine, corresponds to a detec-
tion limit of less than 1 ppb, and this in the presence of 65 
perhaps thousands of complex proteins contained in the blood 
sera. This implementation is presented for illustrative pur-
E. CONCLUSION 
From the foregoing, it will be appreciated that specific 
embodiments of the invention have been described herein for 
purposes of illustration, but that various modifications may be 
made without deviating from the spirit and scope of the inven-
tion. Accordingly, the invention is not limited except as by the 
appended claims. 
I claim: 
1. A device for detecting the presence of a target molecule 
in a vapor, the device comprising: 
a surface acoustic wave resonator producing a waveform; 
a monoclonal antibody immobilized on a surface of the 
surface acoustic waver generator, such that the target 
molecule is an antigen to the monoclonal antibody, such 
that the surface is disposed to receive the vapor; 
an oscillator circuit in communication with the surface 
acoustic wave resonator, the oscillator circuit operative 
to monitor the waveform in real-time using models 
based on time-dependent perturbation theory and to 
respond a signature change to the waveform, the signa-
ture change being indicative of the presence of the target 
molecule in the vapor. 
2. The device of claim 1, wherein the surface acoustic wave 
resonator is fabricated on ST-Quartz. 
3. The device of claim 1, wherein the monoclonal antibody 
is an IgG monoclonal antibody. 
4. The device of claim 1, wherein the target molecule is a 
biological molecule. 
5. The device of claim 1, wherein the target molecule is 
cocame. 
US 7,413,892 B2 
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6. The device of claim 1, wherein the target molecule is a 
cocaine derivative. 
7. The device of claim 6, wherein the monoclonal antibody 
is an antibody ofbenzoylecgonine. 
8. The device of claim 1, wherein the signature change in 
the waveform includes a change in the frequency of the wave-
form. 
8 
9. The device of claim 1, further comprising: a database of 
signatures of responses that are related to a molecular recog-
nition event between the monoclonal antibody and the anti-
gen, wherein the signature change is associated with at least 
one of the signature responses in the database. 
* * * * * 
